Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  

| More

Maintain ADD on Marico - All-round revenue recovery; miss on margin - HDFC Securities

Posted On: 2021-05-03 12:45:44 (Time Zone: UTC)

Mr. Varun Lohchab, Institutional Research Analyst, HDFC Securities and Mr. Naveen Trivedi, Institutional Research Analyst, HDFC Securities

Marico posted an all-round revenue recovery with miss on margin (in-line EBITDA). Revenue/EBITDA grew by 35/13% (HSIE 21/14%). Domestic revenue and volume growth were robust at 37/25%, 13/10% 2-year CAGR, reflecting superior execution. PCNO continued its steady growth momentum, while VAHO saw demand improve for all its brands. Saffola sustained its growth, aided by improved penetration and rising demand for healthy cooking. International, too, saw recovery, led by SAARC and MENA markets, clocking growth of 25% (9% 2-year CAGR). However, high RM inflation impacted margins (GM down >500bps YoY) sharply, despite the improved product mix. Marico ramped up its A&P expenses (up 37% YoY) as the company continued to be aggressive in new launches, but cost saving initiatives in other areas limited the impact on EBITDA margin (dip 300bps YoY). We expect the growth momentum to sustain, and the pressure on margins to ease in FY22, owing to soft RM prices and cost savings. We maintain EPS estimates for FY22/FY23. We value Marico at 40x P/E on Mar-23E EPS to derive a target price of INR 460. Maintain ADD.

Robust revenue growth with share gain: Revenue grew by 35% YoY (-7% in 4QFY20 and +16% in 3QFY21). Domestic volume grew by strong 25% YoY (- 3% in 4QFY20 and +15% in 3QFY21). PCNO saw 38/29% YoY val/vol growth while VAHO saw 22% YoY val/vol growth. Saffola sustained strong momentum and clocked val/vol growth of 43/17% YoY. High edible inflation resulted in exceptional price hike (now at 50%), which led to high value growth. Foods maintained stellar growth momentum in FY21 and reached INR 3bn size (134% growth in 4Q). GT growth in rural stood at 42/15% in 4Q/FY21 and urban at 23/5%. E-commerce posted strong 81/60% YoY growth in 4Q/FY21 (8% of domestic sales). CSD posted 59/-13% YoY in 4Q/FY21.

International revenue up by 25%: International clocked 25% YoY growth. Bangladesh continued its strong performance with 20/15% cc growth in 4Q/FY21, with the non-coconut portfolio seeing 26% growth. MENA/South East Asia/South Africa reported cc growth of 62/13/48% YoY (-50/5/-26%).

RM inflation impacts margin: GM dipped by 513bps YoY (+23bps in 4QFY20 and -223bps in 3QFY21), vs HSIE dip of 226bps YoY. Copra/LLP/HDPE were up 25/29/31% YoY. Employee/Adv/Other expenses grew by 39/37/11% YoY. EBITDA margin contracted by 300bps YoY to 16% (+58bps in 4QFY20 and -100bps in 3QFY21). EBITDA grew by 13% YoY (HSIE 14%). Domestic EBIT margin dipped 463bps YoY (+141bps in 4QFY20) while International margin expanded 266bps YoY (+3bps in 4QFY20).

Call and BS/CF takeaways: (1) Copra price was recently down by 15%; company expects zero copra inflation in FY22; (2) Saffola demand is sustaining, and the company has taken cumulative 50% price hike to pass on RM inflation; (3) food business would achieve INR 5bn in FY22 and INR 8- 10bn by FY24; (4) tax rate of 22-23% in FY22 and 22-24% for 3-4 years; (5) FCF was at INR 19bn vs. INR 10bn in FY20.

Shares of MARICO LTD. was last trading in BSE at Rs.445.4 as compared to the previous close of Rs. 411.65. The total number of shares traded during the day was 1366665 in over 29658 trades.

The stock hit an intraday high of Rs. 452.8 and intraday low of 416.25. The net turnover during the day was Rs. 606230807.

Source: Equity Bulls

Click here to send ur comments or to

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only., its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.

Other Headlines:

Maintain BUY on CreditAccess Grameen - Accelerated write-offs dents earnings - HDFC Securities

Sundram Fasteners Q4 Results Review - HDFC Securities

SRF - Specialty Chemicals continues to shine! - HDFC Securities

Realtors welcome RBI latest stance, expect relief initiatives in next announcement

CreditAccess Grameen - Q4FY21 Result Update - ICICI Securities

JM Financial - Exits FY21 with well contained stress pool; sequential AUM uptick encouraging - ICICI Securities

Hero MotoCorp - Margins remain resilient - ICICI Securities

CEAT - Margin pressures likely to intensify - ICICI Securities

SRF Limited - FY22E growth capped on higher plants utilisation - ICICI Securities

I-direct Instinct - Automotive Axles - ICICI Direct

Quant Pick - Axis Bank - ICICI Direct

Gladiator Stocks - Caplin Point Laboratories - ICICI Direct

Q4FY21 Result Update - Coforge Ltd - ICICI Direct

Tata Consumer Products - Q4FY21 First Cut - ICICI Direct

Coforge Ltd - Q4FY21 Result Update - YES Securities

CreditAccess Grameen - Q4FY21 Result Update - YES Securities

Blue Star - Q4 FY21 first cut - Inline performance - YES Securities

Tata Consumer - 4QFY21 results first cut - YES Securities

Tata Consumer 4QFY21 results first cut - YES Securities

Maintain BUY on CDSL - Strong growth momentum - HDFC Securities

Maintain ADD on L&T Infotech - Steady progression - HDFC Securities

Blue Dart Express - Q4FY21 - The bulge continues - ICICI Securities

Tata Steel - FY22E Net Debt/EBITDA at <1x - ICICI Securities

Larsen & Toubro Infotech - Consistency continues! - ICICI Securities

CEAT - Decent quarter; new capex likely to curtail FCF - ICICI Securities

Q4FY21 Result Update - Alembic Pharma - ICICI Direct

Gladiator Stocks - Cadila Healthcare - ICICI Direct

Q4FY21 Result Update - Larsen & Toubro Infotech - ICICI Direct

RBI Action Update - May 2021 - ICICI Direct

Quant Pick - Aurobindo Pharma - ICICI Direct

Q4FY21 Result Update - Greaves Cotton - ICICI Direct

Adani Total Gas Ltd - Q4FY21 Result Update - YES Securities

L&T Infotech - Q4FY21 Result Update - YES Securities

Bluedart Express - Q4 FY21 first cut - Miss on topline; Profitability improves - YES Securities

Views on the announcement by RBI Governor - Ms. Bekxy Kuriakose, Head - Fixed Income, Principal Asset Management

Views from experts on RBI announcement - May 5, 2021

Maintain REDUCE on RBL Bank - Elevated retail slippages continue - HDFC Securities

Resolution 2.0 measure by RBI to provide relief to real estate linked SME stakeholders

Godrej Properties - Robust quarter; positives fairly priced in - HDFC Securities

RBI Relief 2.0 - May 2021 - Acuité Ratings & Research

MDF Industry - Countervailing duty on MDF recommended; imports may get hit structurally - ICICI Securities

Home First Finance Company - Core earnings steady; profitability buoyed by securitisation income - ICICI Securities

RBL Bank - Modest return profile in the interim; transitioning underway - ICICI Securities

Alembic Pharmaceuticals - US continues to be under pressure - ICICI Securities

Q4FY21 Result Update - SBI Life Insurance - ICICI Direct

Q1CY21 Result Update - Varun Beverages - ICICI Direct

RBL Bank: Views from leading research houses on Q4FY21 results

Q4FY21 Result Update - Supreme Industries - ICICI Direct

Q4FY21 Result Update - Tata Chemicals - ICICI Direct

Larsen & Toubro Infotech - Q4FY21 First Cut - ICICI Direct

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020